Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$0.76
--
Market closed
$0.76
--
Day’s Range― - ―
52-Week Range$0.54 - $2.18
Previous CloseN/A
VolumeN/A
Average Volume (3M)403.14K
Market Cap
$53.90M
Enterprise Value$74.13M
Total Cash (Recent Filing)$40.65M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 06, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding86,267,030
10 Day Avg. Volume517,159
30 Day Avg. Volume403,142
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap1.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.52
Forecast
1Y Price Target
$6.00Price Target Upside689.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.41
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressMeeting the Phase 1b primary endpoint, with both doses well tolerated and no treatment-related serious adverse events, provides meaningful clinical validation. Continued Phase 2 enrollment advances LTI-03 toward a potentially value-creating efficacy readout in IPF.
Low LeverageA debt-free balance sheet limits interest expense, refinancing exposure, and financial leverage risk while the company advances clinical programs. This gives management greater flexibility to allocate capital toward development and financing activities without servicing borrowings.
Differentiated PipelineLTI-03’s multi-pathway mechanism and focus on restoring alveolar structure could differentiate it from existing IPF therapies if later-stage data confirm the biological rationale. The same platform may also support expansion into other pulmonary fibrosis indications.
Bears Say
Pre-Revenue LossesThe absence of commercial revenue leaves Rein dependent on clinical success and future financing rather than internally generated sales. Large ongoing losses reduce financial resilience and make the company’s fundamental outlook highly sensitive to development outcomes and capital access.
Persistent Cash BurnPersistent negative operating and free cash flow means the business is consuming capital while its pipeline remains in development. Until spending is matched by sustainable revenue or materially lower burn, Rein must continue relying on external funding to maintain operations.
Listing And Dilution RiskThe Nasdaq deficiency creates a continuing compliance challenge through February 2027 and could complicate investor access if unresolved. Expanded share authorization improves financing flexibility, but future equity issuance could dilute existing holders while funding ongoing losses.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $0.54 and its highest was $2.18 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $53.90M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 13 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Aug 14, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.17 by $0.07.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 86,267,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.17. Following the earnings report the stock price went up 2.414%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (689.47% Upside)
$6.00 (689.47% Upside)
Blogger Sentiment
Bullish
RNTX Sentiment 100%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.65%
12-Months-Change
Fundamentals
Return on Equity
-234.45%
Trailing 12-Months
Asset Growth
14.78%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
RNTX Stock 12 Month Forecast
Average Price Target
$6.00
▲(689.47% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
XBiotech
―
Elicio Therapeutics
―
Xilio Therapeutics
―
Ownership Overview
1.76% Insiders
1.37% Mutual Funds
0.12% Other Institutional Investors
92.73% Public Companies and
Individual Investors